Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 52
Filter
1.
J Clin Endocrinol Metab ; 105(7)2020 07 01.
Article in English | MEDLINE | ID: mdl-32311038

ABSTRACT

CONTEXT: Autoimmune hypocalciuric hypercalcemia (AHH) is an acquired disorder caused by the presence of blocking autoantibodies against the calcium-sensing receptor (CaSR). Few cases of this condition have been described to date in the literature. OBJECTIVE: The objectives of this study were to describe 2 patients in whom the presence of AHH was suspected and to assess the patients for the presence of CaSR antibodies. METHODS: CaSR antibodies were detected and characterised by immunoprecipitation assays, CaSR peptide ELISAs, and functional assays based on the calcium-stimulated accumulation of inositol-1-phosphate in a mammalian cell line expressing the CaSR. RESULTS: Both patients presented with an acquired form of hypocalciuric hypercalcemia. Mutational analyses of CASR, GNA11, and AP2S1 for familial hypocalciuric hypercalcemia were negative. According to the presence of Hashimoto's disease in 1 patient and latent autoimmune diabetes of adulthood and thyroid autoimmunity in the other, AHH was suspected. Immunoprecipitation assays detected CaSR antibodies in both patients. Analysis of the antibody binding sites revealed 2 main epitopes at amino acids 41-69 and 114-126. Preincubation with purified CaSR antibodies against epitope 114-126 resulted in a significant decrease in inositol-1-phophate accumulation upon calcium-stimulation of mammalian cells expressing the CaSR, suggesting that the antibodies had receptor-blocking activity. CONCLUSIONS: AHH is to be suspected in patients with an acquired biochemical pattern of PTH-dependant hypocalciuric hypercalcemia, especially in those with other concomitant autoimmune diseases. Diagnosis by means of detecting CaSR antibodies may help to better characterise this probably under-reported condition.


Subject(s)
Autoimmune Diseases/immunology , Hypercalcemia/immunology , Receptors, Calcium-Sensing/immunology , Aged , Autoantibodies/blood , Autoimmune Diseases/blood , Hashimoto Disease/complications , Humans , Hypercalcemia/blood , Hypercalcemia/complications , Male , Middle Aged
2.
Transplant Proc ; 52(4): 1178-1182, 2020 May.
Article in English | MEDLINE | ID: mdl-32340747

ABSTRACT

BACKGROUND: Pneumonia caused by opportunistic fungi is a serious complication in immunocompromised patients. Hypercalcemia has been described in renal transplantation associated with Pneumocystis jirovecii (PJP) or Histoplasma capsulatum (HCP) pneumonia. METHODS: We describe 5 patients who underwent kidney transplant between 2014 and 2019 and developed hypercalcemia before the diagnosis of pulmonary fungal infection: 4 patients with PJP and 1 with HCP. We assessed calcium metabolism and kidney function by total and ionized calcium, phosphorus, intact parathormone (iPTH), 25-OH vitamin D, 1,25(OH)2 vitamin D, and serum creatinine levels. RESULTS: Mean albumin-corrected calcium and ionized calcium were 12.56 mg/dL (range, 10.8-13.8 mg/dL) and 1.57 mmol/L (range, 1.43-1.69 mmol/L). Patients were normocalcemic, at 10.12 mg/dL (range, 9.6-10.5 mg/dL), before diagnosis and resolved hypercalcemia after antifungal treatment, at 8.86 mg/dL (range, 8.0-9.5 mg/dL). All patients had low or normal iPTH values, at 29.1 pg/mL (range, <3-44 pg/mL), with higher PTH levels 3 months before diagnosis and after treatment, at 147.3 pg/mL (range, 28.1-479 pg/mL) and 117.5 pg/mL (range, 18.2-245 pg/mL), respectively. The mean value for 25-OH vitamin D was 30.8 ng/mL (range, 14.6-62.8 ng/mL). This supports a PTH-independent mechanism, and we postulated an extrarenal production of 1,25(OH)2 vitamin D. CONCLUSION: In kidney transplant patients, hypercalcemia independent of PTH and refractory to treatment should alert for the possibility of opportunistic fungal pneumonia.


Subject(s)
Hypercalcemia/etiology , Immunocompromised Host , Kidney Transplantation , Mycoses/immunology , Opportunistic Infections/complications , Pneumonia/immunology , Adult , Female , Histoplasmosis/blood , Histoplasmosis/immunology , Humans , Hypercalcemia/blood , Hypercalcemia/immunology , Male , Middle Aged , Mycoses/blood , Mycoses/complications , Opportunistic Infections/immunology , Opportunistic Infections/microbiology , Pneumonia/complications , Pneumonia/microbiology , Pneumonia, Pneumocystis/complications , Pneumonia, Pneumocystis/immunology , Young Adult
3.
Brain ; 142(9): 2737-2755, 2019 09 01.
Article in English | MEDLINE | ID: mdl-31302671

ABSTRACT

Poor vitamin D status is associated with a higher relapse rate and earlier disability in multiple sclerosis. Based on these associations, patients with multiple sclerosis are frequently supplemented with the vitamin D precursor cholecalciferol, although it is unclear whether this regimen is of therapeutic benefit. To model consequences of this common practice, mice were fed for more than 3 months with a low, medium or high dose of cholecalciferol, representative of vitamin D deficiency, modest and disproportionally high supplementation, respectively, in patients with multiple sclerosis. Compared to vitamin D-deprived mice, its moderate supplementation reduced the severity of subsequent experimental autoimmune encephalomyelitis, which was associated with an expansion of regulatory T cells. Direct exposure of murine or human T cells to vitamin D metabolites inhibited their activation. In contrast, mice with 25-(OH) vitamin D levels above 200 nmol/l developed fulminant experimental autoimmune encephalomyelitis with massive CNS infiltration of activated myeloid cells, Th1 and Th17 cells. When dissecting this unexpected outcome, we observed that high, but not medium dose vitamin D had caused mild hypercalcaemia, which rendered T cells more prone to pro-inflammatory activation. Exposing murine or human T cells to equivalent calcium concentrations in vitro enhanced its influx, triggering activation, upregulation of pro-inflammatory gene products and enhanced transmigration across a blood-brain barrier model. These findings suggest that vitamin D at moderate levels may exert a direct regulatory effect, while continuous high dose vitamin D treatment could trigger multiple sclerosis disease activity by raising mean levels of T-cell excitatory calcium.


Subject(s)
Autoimmunity/drug effects , Calcium Signaling/drug effects , T-Lymphocyte Subsets/drug effects , Vitamin D/toxicity , Animals , Blood-Brain Barrier , Calcifediol/blood , Calcium/blood , Calcium/therapeutic use , Calcium/toxicity , Chlorides/blood , Cholecalciferol/adverse effects , Cholecalciferol/therapeutic use , Dose-Response Relationship, Drug , Encephalomyelitis, Autoimmune, Experimental/immunology , Female , Humans , Hypercalcemia/chemically induced , Hypercalcemia/immunology , Lymphocyte Activation/drug effects , Mice , Mice, Inbred C57BL , Mice, Transgenic , Multiple Sclerosis/complications , Multiple Sclerosis/immunology , Phosphates/blood , Sodium/blood , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , Th1 Cells/drug effects , Th1 Cells/immunology , Th17 Cells/drug effects , Th17 Cells/immunology , Vitamin D/blood , Vitamin D Deficiency/complications , Vitamin D Deficiency/drug therapy , Vitamin D Deficiency/immunology
4.
JCI Insight ; 4(8)2019 04 18.
Article in English | MEDLINE | ID: mdl-30996138

ABSTRACT

Biased agonism is a paradigm that may explain the selective activation of a signaling pathway via a GPCR that activates multiple signals. The autoantibody-induced inactivation of the calcium-sensing receptor (CaSR) causes acquired hypocalciuric hypercalcemia (AHH). Here, we describe an instructive case of AHH in which severe hypercalcemia was accompanied by an increased CaSR antibody titer. These autoantibodies operated as biased allosteric modulators of CaSR by targeting its Venus flytrap domain near the Ca2+-binding site. A positive allosteric modulator of CaSR, cinacalcet, which targets its transmembrane domain, overcame this autoantibody effect and successfully corrected the hypercalcemia in this patient. Hence, this is the first study to our knowledge that identifies the interaction site of a disease-causing GPCR autoantibody working as its biased allosteric modulator and demonstrates that cinacalcet can correct the AHH autoantibody effects both in vitro and in our AHH patient. Our observations provide potentially new insights into how biased agonism works and how to design a biased allosteric modulator of a GPCR. Our observations also indicate that the diagnosis of AHH is important because the severity of hypercalcemia may become fatal if the autoantibody titer increases. Calcimimetics may serve as good treatment options for some patients with severe AHH.


Subject(s)
Autoantibodies/metabolism , Calcium-Regulating Hormones and Agents/administration & dosage , Cinacalcet/administration & dosage , Hypercalcemia/drug therapy , Receptors, Calcium-Sensing/metabolism , Aged, 80 and over , Allosteric Regulation/drug effects , Autoantibodies/immunology , Autoantigens/immunology , Binding Sites/drug effects , Calcium/blood , Calcium/metabolism , HEK293 Cells , Humans , Hypercalcemia/blood , Hypercalcemia/diagnosis , Hypercalcemia/immunology , Male , Receptors, Calcium-Sensing/immunology , Receptors, G-Protein-Coupled/immunology , Severity of Illness Index , Signal Transduction/drug effects , Signal Transduction/immunology , Treatment Outcome
5.
J Clin Invest ; 128(12): 5222-5234, 2018 12 03.
Article in English | MEDLINE | ID: mdl-30179220

ABSTRACT

The mechanisms that drive T cell aging are not understood. We report that children and adult telomerase mutation carriers with short telomere length (TL) develop a T cell immunodeficiency that can manifest in the absence of bone marrow failure and causes life-threatening opportunistic infections. Mutation carriers shared T cell-aging phenotypes seen in adults 5 decades older, including depleted naive T cells, increased apoptosis, and restricted T cell repertoire. T cell receptor excision circles (TRECs) were also undetectable or low, suggesting that newborn screening may identify individuals with germline telomere maintenance defects. Telomerase-null mice with short TL showed defects throughout T cell development, including increased apoptosis of stimulated thymocytes, their intrathymic precursors, in addition to depleted hematopoietic reserves. When we examined the transcriptional programs of T cells from telomerase mutation carriers, we found they diverged from older adults with normal TL. Short telomere T cells upregulated DNA damage and intrinsic apoptosis pathways, while older adult T cells upregulated extrinsic apoptosis pathways and programmed cell death 1 (PD-1) expression. T cells from mice with short TL also showed an active DNA-damage response, in contrast with old WT mice, despite their shared propensity to apoptosis. Our data suggest there are TL-dependent and TL-independent mechanisms that differentially contribute to distinct molecular programs of T cell apoptosis with aging.


Subject(s)
Apoptosis/immunology , Growth Disorders , Hypercalcemia , Immunologic Deficiency Syndromes , Metabolic Diseases , Mutation , Nephrocalcinosis , Telomerase , Telomere Homeostasis/immunology , Adult , Aging/genetics , Aging/immunology , Aging/pathology , Animals , Apoptosis/genetics , DNA Damage/immunology , Female , Growth Disorders/complications , Growth Disorders/genetics , Growth Disorders/immunology , Growth Disorders/pathology , Humans , Hypercalcemia/complications , Hypercalcemia/genetics , Hypercalcemia/immunology , Hypercalcemia/pathology , Immunologic Deficiency Syndromes/etiology , Immunologic Deficiency Syndromes/genetics , Male , Metabolic Diseases/complications , Metabolic Diseases/genetics , Metabolic Diseases/immunology , Metabolic Diseases/pathology , Mice , Mice, Knockout , Nephrocalcinosis/complications , Nephrocalcinosis/genetics , Nephrocalcinosis/immunology , Nephrocalcinosis/pathology , Primary Immunodeficiency Diseases , T-Lymphocytes/immunology , T-Lymphocytes/pathology , Telomerase/genetics , Telomerase/immunology
6.
J Natl Cancer Inst ; 110(7): 787-790, 2018 07 01.
Article in English | MEDLINE | ID: mdl-29365144

ABSTRACT

Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is a highly aggressive monogenic cancer driven by SMARCA4 mutations. Here, we report responses to anti-PD1 immunotherapy in four patients and characterize the immune landscape of SCCOHT tumors using quantitative immunofluorescence and gene expression profiling. Unexpectedly for a low mutation burden cancer, the majority of the tumors (eight of 11 cases) demonstrated PD-L1 expression with strong associated T-cell infiltration (R2 = 0.60-0.95). PD-L1 expression was detected in both tumor and stromal cells, with macrophages being the most abundant PD-L1-positive cells in some tumors (three of 11 cases). Transcriptional profiling revealed increased expression of genes related to Th1 and cytotoxic cell function in PD-L1-high tumors, suggesting that PD-L1 acts as a pathway of adaptive immune resistance in SCCOHT. These findings suggest that although SCCOHT are low-mutational burden tumors, their immunogenic microenvironment resembles the landscape of tumors that respond well to treatment with PD-1/PD-L1 blockade.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Carcinoma, Small Cell/drug therapy , Carcinoma, Small Cell/immunology , Hypercalcemia , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/immunology , Tumor Microenvironment/immunology , Adolescent , Adult , B7-H1 Antigen/antagonists & inhibitors , B7-H1 Antigen/immunology , Carcinoma, Small Cell/genetics , Carcinoma, Small Cell/pathology , Cell Cycle Checkpoints/drug effects , Cell Cycle Checkpoints/immunology , DNA Helicases/genetics , Female , Humans , Hypercalcemia/complications , Hypercalcemia/genetics , Hypercalcemia/immunology , Hypercalcemia/pathology , Immunotherapy/methods , Mutation , Nuclear Proteins/genetics , Ovarian Neoplasms/genetics , Ovarian Neoplasms/pathology , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Programmed Cell Death 1 Receptor/immunology , Rationalization , Transcription Factors/genetics , Tumor Microenvironment/drug effects , Young Adult
7.
Eur J Endocrinol ; 177(1): K1-K6, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28515208

ABSTRACT

OBJECTIVE: Autoimmune lymphocytic parathyroiditis and acquired hypocalciuric hypercalcemia associated with autoantibodies against the calcium-sensing receptor (anti-CaSR) are rare and poorly understood conditions. Here, we describe a patient with acquired parathyroid hormone (PTH)-dependent hypercalcemia with associated hypocalciuria, found to have true lymphocytic parathyroiditis on histopathology, and circulating anti-CaSR antibodies in serum. DESIGN AND METHODS: A 64-year-old woman was referred to our clinic for persistent hypercalcemia after a subtotal parathyroidectomy. She was normocalcemic until the age of 63 years when she was diagnosed with primary hyperparathyroidism. She underwent subtotal parathyroidectomy with appropriate intraoperative PTH decline. Two weeks post-parathyroidectomy, she presented with persistent hypercalcemia and hyperparathyroidism. Urine studies revealed an inappropriately low 24-h urine calcium (Ca)/creatinine clearance ratio. Surgical pathology was consistent with true lymphocytic parathyroiditis with lymphoid follicles. The presence of circulating anti-CaSR antibodies was detected by immunoprecipitation of CaSR by the patient's serum. After a 4-week course of prednisone, serum Ca and PTH normalized, and her anti-CaSR titers declined. She remains normocalcemic 10 months after the discontinuation of glucocorticoid therapy. We present this patient in the context of the relevant published literature on lymphocytic parathyroiditis and acquired hypocalciuric hypercalcemia related to anti-CaSR antibodies. CONCLUSIONS: Autoimmune lymphocytic parathyroiditis and acquired hypocalciuric hypercalcemia associated with anti-CaSR antibodies is a very rare yet important condition to be considered in a patient with acquired PTH-dependent hypercalcemia with inappropriate hypocalciuria. Although subtotal parathyroidectomy is unlikely to correct the hypercalcemia, this entity may respond to a short course of prednisone therapy.


Subject(s)
Autoantibodies/immunology , Glucocorticoids/therapeutic use , Hypercalcemia/etiology , Hyperparathyroidism, Primary/etiology , Receptors, Calcium-Sensing/immunology , Anti-Inflammatory Agents/therapeutic use , Calcium/blood , Diabetes Mellitus, Type 2/complications , Female , Humans , Hypercalcemia/immunology , Hyperparathyroidism, Primary/immunology , Hyperparathyroidism, Primary/therapy , Middle Aged , Parathyroid Hormone/blood , Parathyroidectomy , Prednisone/therapeutic use
9.
Endocr J ; 61(4): 303-9, 2014.
Article in English | MEDLINE | ID: mdl-24240576

ABSTRACT

The classical model of G protein-coupled receptor (GPCR) activation is the two-state model, in which the GPCR exists in equilibrium between an active and inactive state. Based on this model, GPCR ligands have been classified as agonists, inverse agonists, or antagonists depending on their actions in shifting this equilibrium. Recently, however, accumulating evidence has indicated that GPCRs may exist in multiple active and inactive conformational states. In this situation, each ligand recognizes and stabilizes a specific conformation of the GPCR, leading to a set of specific biological effects. Based on this new model, a unique agonist or a combination of the usual agonist and an allosteric modulator may enable activation of a specific signaling pathway via a GPCR that activates multiple signals (biased agonism, functional selectivity). The calcium-sensing receptor autoantibody that we have identified in the serum of a patient with acquired hypocalciuric hypercalcemia (AHH) is the first example of a biased allosteric modulator of a GPCR working in a pathophysiological context. Our findings may indicate the presence of physiological allosteric modulators and provide new directions for the future drug development.


Subject(s)
Autoantibodies/analysis , G-Protein-Coupled Receptor Kinases/metabolism , Hypercalcemia/metabolism , Models, Biological , Signal Transduction , Allosteric Regulation , Animals , Autoantibodies/metabolism , Enzyme Activation , G-Protein-Coupled Receptor Kinases/chemistry , Humans , Hypercalcemia/blood , Hypercalcemia/immunology , Ligands , Protein Conformation , Receptors, Calcium-Sensing/agonists , Receptors, Calcium-Sensing/chemistry , Receptors, Calcium-Sensing/metabolism
10.
Am J Kidney Dis ; 62(6): 1151-4, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23810542

ABSTRACT

We present a case of an 82-year-old woman with elevated parathyroid hormone (PTH) levels, hypocalciuria, hypercalcemia, and stage 3 chronic kidney disease. Hypocalciuria initially was attributed to chronic kidney disease, and hypercalcemia was attributed to primary hyperparathyroidism. Subsequent laboratory studies showed autoantibodies in the patient's serum directed against the calcium-sensing receptor (CaSR). Functional testing in a CaSR-transfected human embryonic kidney-293 cell line showed that the patient's antibodies inhibited CaSR-mediated intracellular signaling that ordinarily would have been stimulated by extracellular calcium ions. Her serum calcium and PTH levels were normalized by treatment with the calcimimetic cinacalcet. We advise consideration of the presence of inhibitory autoantibodies directed at the CaSR in patients with hypercalcemic hyperparathyroidism and unexplained hypocalciuria or with confounding conditions affecting interpretation of urinary calcium measurement. A calcimimetic is an effective treatment for the hypercalcemia and elevated PTH levels in acquired hypocalciuric hypercalcemia caused by inhibitory anti-CaSR autoantibodies.


Subject(s)
Autoantibodies/blood , Autoimmune Diseases/etiology , Hypercalcemia/etiology , Kidney Failure, Chronic/complications , Receptors, Calcium-Sensing/immunology , Aged, 80 and over , Autoimmune Diseases/diagnosis , Autoimmune Diseases/immunology , Calcium/blood , Female , Humans , Hypercalcemia/diagnosis , Hypercalcemia/immunology , Hyperparathyroidism, Secondary/diagnosis , Hyperparathyroidism, Secondary/etiology , Hyperparathyroidism, Secondary/immunology , Kidney Failure, Chronic/immunology , Receptors, Calcium-Sensing/antagonists & inhibitors
11.
Eur J Clin Invest ; 43(5): 476-82, 2013 May.
Article in English | MEDLINE | ID: mdl-23521420

ABSTRACT

BACKGROUND: Polymorphonuclear leucocytes (PMNLs) play a key role in the nonspecific immune defence. Cinacalcet reduces serum calcium levels in kidney transplant recipients with mineral bone disorder associated with chronic kidney disease. We investigated essential functions of PMNLs of kidney transplant recipients with and without hypercalcaemia and with and without cinacalcet therapy. SUBJECTS AND METHODS: Oxidative burst, phagocytosis, apoptosis and intracellular calcium concentrations of PMNLs from normocalcaemic kidney transplant patients without (KT-NC) or with cinacalcet intake (KT-NC/CI), hypercalcaemic kidney transplant patients (KT-HC) and healthy subjects (HS) were investigated. RESULTS: Stimulation of oxidative burst of PMNLs from KT-HC patients by phorbol-12-myristate-13-acetate or Escherichia coli was significantly attenuated compared with PMNLs from KT-NC, KT-NC/CI and HS. Apoptosis of PMNLs from KT-HC patients was significantly decreased compared with cells from KT-NC, KT-NC/CI and HS. Apoptosis correlated significantly with serum calcium concentrations. Intracellular calcium concentrations and phagocytosis of PMNLs did not differ between groups. CONCLUSIONS: Our data indicate that stimulation of PMNL oxidative burst and apoptosis is significantly diminished in kidney transplant patients with hypercalcaemia, while kidney transplant patients with serum calcium levels normalized by cinacalcet have normal PMNL functions despite immunosuppressive therapy.


Subject(s)
Calcimimetic Agents/therapeutic use , Hypercalcemia/drug therapy , Kidney Transplantation , Naphthalenes/therapeutic use , Neutrophils/physiology , Apoptosis/drug effects , Calcium/blood , Cinacalcet , Female , Humans , Hypercalcemia/immunology , Male , Middle Aged , Phagocytosis , Respiratory Burst/drug effects
12.
J Clin Endocrinol Metab ; 96(3): 672-80, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21159843

ABSTRACT

CONTEXT: Autoantibodies directed against the calcium-sensing receptor (CaSR) have been reported in several individuals with various autoimmune disorders and PTH-mediated hypercalcemia. Previously, glucocorticoid treatment has been shown to decrease the CaSR autoantibody titers and normalize the hypercalcemia in a patient with autoimmune hypocalciuric hypercalcemia (AHH). OBJECTIVE: The objective of the study was to evaluate a patient with AHH for the presence of blocking autoantibodies against the CaSR and to monitor her biochemical and serological responses to a trial of glucocorticoid therapy. RESULTS: Glucocorticoid treatment had no effect on serum total or ionized calcium concentration or serum PTH levels, all of which remained at higher than normal levels. In contrast, on prednisone, urinary calcium excretion increased from overtly hypocalciuric levels to normal values. Anti-CaSR autoantibodies were detected at similar levels in the patient's serum before, during, and after glucocorticoid treatment. Functional testing of these antibodies showed that they inhibited the stimulatory effect of extracellular Ca(2+) on ERK1/2 but did not suppress the calcium-induced accumulation of inositol-1-phosphate. CONCLUSIONS: We report a patient with AHH with frankly elevated PTH levels who was found to have autoantibodies against the CaSR. The hypercalcemia and CaSR autoantibody titers failed to respond to glucocorticoid therapy, unlike a previously reported patient with similar clinical and biochemical features. The anti-CaSR antibody-mediated inhibition of CaSR-stimulated ERK1/2 activity, but not of inositol-1-phosphate accumulation, suggests that ERK1/2 may mediate, at least in part, the regulation of PTH secretion and urinary calcium excretion by the CaSR.


Subject(s)
Autoantibodies/immunology , Autoimmune Diseases/drug therapy , Autoimmune Diseases/immunology , Calcium/urine , Glucocorticoids/therapeutic use , Hypercalcemia/drug therapy , Hypercalcemia/immunology , Receptors, Calcium-Sensing/antagonists & inhibitors , Receptors, Calcium-Sensing/immunology , Aged , Antibodies, Antinuclear/analysis , Antibodies, Blocking/immunology , Calcium/pharmacology , Drug Resistance , Extracellular Signal-Regulated MAP Kinases/metabolism , Female , Humans , Immunoglobulin E/blood , Immunoprecipitation , Inositol Phosphates/metabolism , Parathyroid Hormone/metabolism , Phosphorylation , Stimulation, Chemical , Type C Phospholipases/metabolism
13.
Am J Emerg Med ; 27(5): 629.e1-3, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19497480

ABSTRACT

The emergence of highly active antiretroviral therapy using combinations of reverse transcriptase and protease inhibitors ushered the dawn of a new era in management of human immunodeficiency virus infection. Immune reconstitution inflammatory syndrome is an adverse consequence of the restoration of pathogen-specific immune responses during the early phase of antiretroviral therapy. Pre-existing subclinical or opportunistic infections become apparent or even "worse" as host immunological inflammatory responses are "switched on". Major reductions in plasma viral load were associated with substantial increases in circulating CD4 T-cell lymphocyte counts and restoration of immune function. The rapid reversal in immune function gives rise to paradoxical therapeutic reaction by rebuilding host immune responses. Herein, a hidden culprit responsible for tuberculosis-associated immune reconstitution characterized by severe hypercalcemia and acute renal failure is reported, illustrating the compounded therapeutic strategy in AIDS patients.


Subject(s)
Antiretroviral Therapy, Highly Active , HIV Infections/drug therapy , HIV Infections/immunology , HIV-1 , Hypercalcemia/immunology , Immune Reconstitution Inflammatory Syndrome/chemically induced , Adult , Humans , Hypercalcemia/chemically induced , Hypercalcemia/diagnosis , Immune Reconstitution Inflammatory Syndrome/diagnosis , Male , Viral Load
14.
Vet Pathol ; 46(5): 1003-14, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19429977

ABSTRACT

Infection with human T-cell leukemia virus type 1 (HTLV-1) leads sometimes to the development of adult T-cell lymphoma/leukemia (ATL), which is invariably fatal and often associated with humoral hypercalcemia of malignancy. The transformation of infected CD4 T cells and the pathogenesis of leukemia have been studied with great limitation in tissue culture and patients. To better understand the pathogenesis and perform preclinical drug studies, animal models of ATL are urgently needed. In mice, inoculation of HTLV-1 cell lines mostly leads to development of localized lymphomas. To develop an ATL animal model with leukemic spread of ATL cells, mouse strains with different well-defined immune deficiencies were inoculated intraperitoneally with different HTLV-1-infected cell lines (ACH.2, C8166, MT-2, MET-1). Inoculation of MET-1 cells into NOD/SCID mice provided the best model system for slowly developing T-cell leukemia with multiple organ involvement. In leukemic mice, an increase in serum calcium levels correlated with expression of receptor activator of nuclear factor kappa-light-chain-enhancer of activated B cells ligand on leukemic cells and secretion of parathyroid hormone-related protein and interleukin-6. In contrast to the other cell lines that did not spread systemically, MET-1 expressed both the adhesion molecules CD11a (LFA-1alpha) and CD49d (VLA-4alpha) and produced or induced expression of matrix metalloproteinases 1, 2, 3, and 9, thus underlining the importance of these molecules in the spread of adult T-cell leukemia cells. The MET-1/NOD/SCID model will be useful for developing interventions against invasion and spread of leukemic cells and subsequent humoral hypercalcemia of malignancy.


Subject(s)
Disease Models, Animal , Hypercalcemia/etiology , Leukemia-Lymphoma, Adult T-Cell/immunology , Mice, Inbred NOD/immunology , Mice, SCID/immunology , Animals , Basigin/immunology , Blotting, Western/veterinary , CD11a Antigen/immunology , Cell Line , Female , Humans , Hypercalcemia/immunology , Immunohistochemistry/veterinary , Integrin alpha4/immunology , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase 9/immunology , Mice , Mice, Knockout , Parathyroid Hormone-Related Protein/genetics , Parathyroid Hormone-Related Protein/immunology , RANK Ligand/immunology , RNA/chemistry , RNA/genetics , Receptors, Chemokine/genetics , Receptors, Chemokine/immunology , Reverse Transcriptase Polymerase Chain Reaction/veterinary
16.
J Immunol ; 179(1): 266-74, 2007 Jul 01.
Article in English | MEDLINE | ID: mdl-17579046

ABSTRACT

Receptor activator of NF-kappaB (RANK) and its ligand (RANKL) are essential for osteoclast formation, function, and survival. Osteoprotegerin (OPG) inhibits RANK signaling by sequestering RANKL. This study evaluated the antiosteoclast and immunoregulatory effects of mouse rRANK-Fc, which, similar to OPG, can bind RANKL. The effect of RANKL inhibition by RANK-Fc on osteoclast function was determined by inhibition of vitamin D(3) (1,25(OH)(2)D(3))-induced hypercalcemia. Mice were injected with a single dose of 0, 10, 100, 500, or 1000 microg of RANK-Fc; 100 microg of OPG-Fc; or 5 microg of zoledronate 2 h before 1,25(OH)(2)D(3) challenge on day 0, and sacrificed on days 1, 2, 4, 6, 8, 12, 16, and 20. RANK-Fc doses of 100 or 500 microg were tested in a mouse respiratory influenza virus host-resistance model. A single dose of RANK-Fc > or =100 microg suppressed elevation of serum calcium levels and suppressed the bone turnover marker serum pyridinoline at day 4 and later time points, similar to those observed with OPG-Fc and zoledronate (p < or = 0.01 vs controls). By day 6, both immature and mature osteoclasts were depleted by high doses of RANK-Fc (500 and 1000 microg) or 100 microg of OPG-Fc. RANK-Fc doses of 100 or 500 microg had no detectable effect on immune responses to influenza infection, as measured by activation of cytotoxic T cell activity, influenza-specific IgG response, and virus clearance. RANK-Fc inhibition of RANKL has antiosteoclast activity at doses that have no detectable immunoregulatory activity, suggesting that RANKL inhibitors be further studied for their potential to treat excess bone loss.


Subject(s)
Bone Resorption/immunology , Bone Resorption/prevention & control , Hypercalcemia/immunology , Hypercalcemia/prevention & control , Influenza A Virus, H3N2 Subtype/immunology , Orthomyxoviridae Infections/immunology , RANK Ligand/antagonists & inhibitors , Animals , Bone Resorption/metabolism , Diphosphonates/administration & dosage , Disease Models, Animal , Dose-Response Relationship, Immunologic , Female , Hydroxycholecalciferols/toxicity , Hypercalcemia/metabolism , Imidazoles/administration & dosage , Immunity, Innate , Immunoglobulin G/administration & dosage , Longitudinal Studies , Male , Mice , Mice, Inbred C57BL , Orthomyxoviridae Infections/pathology , Orthomyxoviridae Infections/physiopathology , Osteoprotegerin/administration & dosage , Osteoprotegerin/immunology , Receptor Activator of Nuclear Factor-kappa B/antagonists & inhibitors , Recombinant Fusion Proteins/administration & dosage , Zoledronic Acid
17.
Proc Natl Acad Sci U S A ; 104(13): 5443-8, 2007 Mar 27.
Article in English | MEDLINE | ID: mdl-17372216

ABSTRACT

The seven-spanning calcium-sensing receptor (CaSR) activates multiple G proteins including Gq and Gi, and thereby activates a variety of second messengers and inhibits parathyroid hormone (PTH) secretion. However, the exact signaling mechanisms underlying the functional activity of CaSR are not yet fully understood. The heterozygous inactivation of CaSR or its inhibition by antibody blocking results in either familial hypocalciuric hypercalcemia or acquired hypocalciuric hypercalcemia (AHH), respectively. Here, we report the identification of a unique CaSR autoantibody in an AHH patient. Paradoxically, we find that this autoantibody potentiates the Ca(2+)/Gq-dependent accumulation of inositol phosphates by slightly shifting the dose dependence curve of the Ca(2+) mediated activation of phosphatidylinositol turnover to the left, whereas it inhibits the Ca(2+)/Gi-dependent phosphorylation of ERK1/2 in HEK293 cells stably expressing human CaSR. Treatment of these same cells with a calcimimetic, NPS-R-568, augments the CaSR response to Ca(2+), increasing phosphatidylinositol turnover and ERK1/2 phosphorylation, and overcoming the autoantibody effects. Our observations thus indicate that a calcium-stimulated CaSR primed by a specific autoantibody adopts a unique conformation that activates Gq but not Gi. Our findings also suggest that CaSR signaling may act via both Gq and Gi to inhibit PTH secretion. This is the first report of a disease-related autoantibody that functions as an allosteric modulator and maintains G protein-coupled receptors (GPCRs) in a unique active conformation with its agonist. We thus speculate that physiological modulators may exist that enable an agonist to specifically activate only one signaling pathway via a GPCR that activates multiple signaling pathways.


Subject(s)
Autoantibodies/chemistry , Hypercalcemia/immunology , Hypocalcemia/immunology , Receptors, Calcium-Sensing/chemistry , Aged , Allosteric Site , Aniline Compounds/pharmacology , Calcium/agonists , Cell Line , Humans , Hypercalcemia/diagnosis , Hypophosphatemia/diagnosis , Male , Parathyroid Hormone/chemistry , Phenethylamines , Propylamines , Protein Conformation , Signal Transduction
18.
J Clin Exp Hematop ; 46(1): 11-23, 2006 Mar.
Article in English | MEDLINE | ID: mdl-17058804

ABSTRACT

Human Vgamma2Vdelta2 T cells recognize nonpeptide antigens derived from pathogenic microbes in a TCR-dependent manner, such as pyrophosphomonoester compounds from mycobacteria and malaria parasite and alkyl amines from Proteus, suggesting that this subset of gamma delta T cells is involved in infectious immunity. The precise recognition mechanism has been delineated using a site-directed mutagenesis strategy based on crystal structure of gamma delta TCR. On the other hand, several lines of evidence indicate that human gamma delta T cells are involved in tumor immunity. Although activated gamma delta T cells exhibit a cytolytic activity against most of tumor cells, only a small fraction of tumor cells, like Burkitt lymphoma cells and multiple myeloid cells, is recognized by human gamma delta T cells in a TCR-dependent manner. This implicates that human gamma delta T cells have two distinct pathways for anti-tumor immunity. One is a natural killer-like pathway and the other is a TCR-dependent pathway. Recently, it was shown that treatment of human tumor cells with nitrogen-containing bisphosphonates, therapeutic drugs for hypercalcemia in malignancy, generated antigenic structure on the surface of tumor cells, which could be recognized by human gamma delta T cells in a TCR-dependent manner. This tumor labeling system may lead to a novel strategy for cancer immunotherapy.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Diphosphonates/therapeutic use , Immunotherapy , Neoplasms/immunology , Neoplasms/therapy , Receptors, Antigen, T-Cell, gamma-delta/immunology , T-Lymphocytes/immunology , Animals , Bone Density Conservation Agents/immunology , Diphosphonates/immunology , Humans , Hypercalcemia/drug therapy , Hypercalcemia/etiology , Hypercalcemia/immunology , Immunotherapy/methods , Lymphocyte Activation/drug effects , Mice , Neoplasms/complications
20.
J Immunol ; 175(2): 917-25, 2005 Jul 15.
Article in English | MEDLINE | ID: mdl-16002690

ABSTRACT

IL-4 is an important immune cytokine that regulates bone homeostasis. We investigated the molecular mechanism of IL-4 action on bone-resorbing mature osteoclasts. Using a highly purified population of mature osteoclasts, we show that IL-4 dose-dependently inhibits receptor activator of NF-kappaB ligand (RANKL)-induced bone resorption by mature osteoclasts. We detected the existence of IL-4R mRNA in mature osteoclasts. IL-4 decreases TRAP expression without affecting multinuclearity of osteoclasts, and inhibits actin ring formation and migration of osteoclasts. Interestingly, IL-4 inhibition of bone resorption occurs through prevention of RANKL-induced nuclear translocation of p65 NF-kappaB subunit, and intracellular Ca(2+) changes. Moreover, IL-4 rapidly decreases RANKL-stimulated ionized Ca(2+) levels in the blood, and mature osteoclasts in IL-4 knockout mice are sensitive to RANKL action to induce bone resorption and hypercalcemia. Furthermore, IL-4 inhibits bone resorption and actin ring formation by human mature osteoclasts. Thus, we reveal that IL-4 acts directly on mature osteoclasts and inhibits bone resorption by inhibiting NF-kappaB and Ca(2+) signaling.


Subject(s)
Bone Resorption/immunology , Bone Resorption/prevention & control , Calcium Signaling/immunology , Cell Differentiation/immunology , Interleukin-4/physiology , NF-kappa B/physiology , Osteoclasts/immunology , Osteoclasts/metabolism , Acid Phosphatase/antagonists & inhibitors , Acid Phosphatase/biosynthesis , Acid Phosphatase/genetics , Actins/antagonists & inhibitors , Actins/metabolism , Active Transport, Cell Nucleus/genetics , Active Transport, Cell Nucleus/immunology , Adult , Animals , Bone Resorption/pathology , Calcium Signaling/genetics , Carrier Proteins/administration & dosage , Carrier Proteins/antagonists & inhibitors , Carrier Proteins/physiology , Cell Differentiation/genetics , Cell Migration Inhibition , Glycoproteins/antagonists & inhibitors , Glycoproteins/biosynthesis , Glycoproteins/genetics , Humans , Hypercalcemia/immunology , Hypercalcemia/metabolism , Hypercalcemia/pathology , Interleukin-4/deficiency , Interleukin-4/genetics , Intracellular Fluid/immunology , Intracellular Fluid/metabolism , Isoenzymes/antagonists & inhibitors , Isoenzymes/biosynthesis , Isoenzymes/genetics , Male , Membrane Glycoproteins/administration & dosage , Membrane Glycoproteins/antagonists & inhibitors , Membrane Glycoproteins/physiology , Mice , Mice, Inbred BALB C , Mice, Knockout , NF-kappa B/antagonists & inhibitors , NF-kappa B/metabolism , Osteoclasts/enzymology , Osteoclasts/pathology , Osteoprotegerin , RANK Ligand , RNA, Messenger/antagonists & inhibitors , RNA, Messenger/biosynthesis , Receptor Activator of Nuclear Factor-kappa B , Receptors, Calcitonin/antagonists & inhibitors , Receptors, Calcitonin/biosynthesis , Receptors, Calcitonin/genetics , Receptors, Cytoplasmic and Nuclear/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL
...